Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19 - Aix-Marseille Université Access content directly
Journal Articles SCIENTIFIC REPORTS Year : 2022

Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19

Noemie Resseguier
  • Function : Author
Dammar Bouchouareb
  • Function : Author
Jean Dhorne
  • Function : Author
Bertrand Dussol
  • Function : Author
Ariane Duval
  • Function : Author
Julien Faraut
  • Function : Author
Toscane Fourie
  • Function : Author
Philippe Giaime
  • Function : Author
Mourad Hallah
  • Function : Author
Dominique Jaubert
  • Function : Author
Oceane Jehel
  • Function : Author
Tristan Legris
  • Function : Author
Stephane Liotatis
  • Function : Author
Valerie Moal
  • Function : Author
Nathalie Pedinielli
  • Function : Author
Marion Pelletier
  • Function : Author
Manon Romeu-Giannoli
  • Function : Author
Mariela Saba
  • Function : Author
Marion Sallee
  • Function : Author
Laurent Samson
  • Function : Author
Adriana Saveanu
  • Function : Author
Violaine Scarfogliere
  • Function : Author
Pascale Sebahoun
  • Function : Author
Romain Vial
  • Function : Author
Gaetan Lebrun
  • Function : Author

Abstract

Hemodialysis (HD) patients are at risk for severe COVID-19 and cannot comply with social distancing. SARS-COV2 seroprevalence in French patients and caregivers after the first wave of COVID-19 is unknown. SeroCOVIDial is a prospective study conducted between June and December 2020. SARS-COV2 seroprevalence was evaluated by a rapid serological test (BIOSYNEX) in HD patients and caregivers, and the presence or not of anti-SARS-COV2 neutralizing or non-neutralizing antibodies in patients was also determined by ELISA and seroneutralization. In June 2020, 451 HD patients and 238 caregivers were included. Overall SARS-COV2 seroprevalence was 8.4% (patients) and 6.7% (caregivers), and was 87.1% (patients) and 90.0% (caregivers) in participants with a previously documented SARS-COV2 infection. Overall seroprevalence reached 13.8% (patients) and 12.6% (caregivers) following the second epidemic wave. During the follow-up, 38 (8.4%) patients died (9 of COVID-19). Among the 44 (10.6%) patients who became infected, only two were seropositive at M0. The levels of anti-SARS-COV2 antibodies decreased over time in patients and caregivers. The BIOSYNEX test showed 82.9% sensitivity and 97.7% specificity. Prevalence of anti-SARS-COV2 antibodies was low in HD patients and caregivers after the first epidemic wave but rose after the second wave. A rapid serological test showed good performances and could be useful for future monitoring of anti-SARS-COV2 antibodies.

Domains

Genetics

Dates and versions

hal-03780351 , version 1 (19-09-2022)

Identifiers

Cite

Thomas Robert, Guillaume Lano, Noemie Resseguier, Mickael Bobot, Dammar Bouchouareb, et al.. Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. SCIENTIFIC REPORTS, 2022, 12 (1), pp.11972. ⟨10.1038/s41598-022-15913-0⟩. ⟨hal-03780351⟩
17 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More